From October 1, 2021 to October 31, 2021, the company has repurchased 273,210 shares, representing 0.19% for $9.5 million. With this, the company has completed the repurchase of 22,250,346 shares, representing 15.7% for $550 million under the buyback announced on November 4, 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.48 USD | -0.13% | -0.74% | +23.05% |
05-22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.05% | 5.8B | |
+9.99% | 114B | |
+12.01% | 107B | |
-3.07% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.90% | 17.51B | |
-39.36% | 17.17B | |
+5.82% | 14.14B | |
+33.05% | 12.2B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on November 4, 2019.